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The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with
metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial. Sixty-three patients with
MBC, previously treated with chemotherapy including anthracycline and/or taxanes, were treated with mitoxantrone 10 or
12mgm
 2 intravenously on day 1 plus gemcitabine in escalating doses from 600 to 1200mgm
 2 intravenously on days 1 and 8,
every 3 weeks. In phase I, on 23 patients entered on study, dose-limiting toxicity occurred at the dosage of 1200mgm
 2 gemcitabine
and 10mgm
 2 mitoxantrone, with three out of five patients developing grade 4 neutropenia. In phase II, with gemcitabine
administered at 1000mgm
 2 and mitoxantrone at 10mgm
 2, 12 (30%) out of 40 assessable patients responded, even if no
complete response was obtained. Moreover, stable disease was observed in eight (20%) patients. The median time to treatment
failure was 22 weeks (range, 2–33), and median survival was 42 weeks (range, 2–92). Grade 3 and 4 neutropenia were observed in
12 (30%) and one (2.5%) cases respectively; grade 3 thrombocytopenia was observed in two patients (5%), grade 2 mucositis in two
patients (5%), grade 3 anaemia in two patients (5%), grade 3 alopecia in one patient (2.5%) and asymptomatic cardiotoxicity in three
patients (8%), respectively. In conclusion, the doses of 10mgm
 2 (day 1) for mitoxantrone and 1000mgm
 2 for gemcitabine (days
1–8) every 3 weeks resulted active and safe in MBC. Further investigations in less heavily pretreated patients are warranted.
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Breast cancer is the most common malignancy affecting women in
USA and in Europe with an incidence rate of 21 and 28%,
respectively, among all causes of cancer (Black et al, 1997; Greenlee
et al, 2000). Despite the progress achieved in screening and
management of the early stages of the disease, 40–60% of subjects
with this malignancy will develop metastases and will ultimately
die of the disease. A number of cytotoxic drugs have shown activity
in these patients, but actually combinations of taxanes and
anthracyclines are the most extensively utilised as first-line
treatment (Perez, 1999). In fact, with these regimens an overall
response rate (ORR) of 40–80% with a complete response (CR) of
less than 20% is currently achievable in not pretreated patients
(Dieras, 1998; De Lena et al, 2000; Pagani et al, 2000). However, the
increasing use of anthracyclines and taxanes in the adjuvant
setting has led to a limitation of the role of these drugs in relapsed
patients (Hortobagy and Buzdar, 1993; Early Breast Cancer
Trialists’ Collaborative Group, 1998; Goldhrisch et al, 2000). As a
consequence, new cytotoxic drugs and new combination therapies
are needed as second-line treatment.
Mitoxantrone hydrochloride is an anthracene derivative whose
effectiveness in metastatic breast carcinoma has been well
documented. In fact, this drug as single agent is able to achieve
30–36% responses in first-line chemotherapy and about 20%
responses in second line. Its toxicity includes limited vomiting,
oral mucositis, hair loss and cardiotoxicity (Smith et al, 1983;
Mouridsen et al, 1985; Robertson et al, 1989; Brufman et al, 1993).
Gemcitabine hydrochloride, a novel nucleoside analogue, offers
proven activity against a range of solid tumours (Gatzemeier et al,
1996; Moore, 1996; Shapiro et al, 1996; Stadler et al, 1997). In
particular, in metastatic breast cancer, gemcitabine alone yielded
response rates of 25–46% in the first phase II studies (Hertel et al,
1990; Carmichael et al, 1995; Blackstein et al, 1997; Spielmann et al,
1997; Possinger et al, 1999). Haematological and nonhaemato-
logical side effects were mild, with dose reductions, treatment
delays or withdrawals only seldom reported. Moreover, also the
first phase II studies of this cytotoxic drug in combination with
anthracyclines, docetaxel or vinorelbine demonstrated a good
toxicity profile and promising results (Mavroudis et al, 1999;
Nicolaides et al, 2000; Pe ´rez-Manga et al, 2000). The rationale for
the combination of gemcitabine plus mitoxantrone was the
therapeutic efficacy, the low systemic toxicity and the high
tolerability of both drugs. Thus, the aim of this phase I/II study
was to evaluate the maximum tolerated dose (MTD), the activity
(response, time to treatment failure, survival) and toxicity profile
of this combination in patients with stage IV breast cancer patients
previously treated with chemotherapy regimens including taxanes
or anthracyclines.
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lPATIENTS AND METHODS
Patients with histologically proven, measurable locally advanced or
metastatic breast cancer, refractory or resistant to hormone
therapy, who had previously received chemotherapy including
anthracyclines or taxanes, were eligible for this study. However,
patients may have received as maximum anthracycline dosage a
cumulative dose of 300 or 540mgm
 2 of doxorubicin and
epidoxorubicin, respectively. The other eligibility criteria were:
age between 18 and 70 years; Eastern Cooperative Oncology Group
(ECOG) performance status (PS) p2; expected survival of X3
months; good bone marrow function (absolute granulocyte count
X4000ml
 1, platelet count X100.000ml
 1, and haemoglobin
X11gdl
 1); adequate hepatic and renal function, including AST,
ALT, bilirubin, alkaline phosphatase and serum creatinine values
p1.25 times the upper limit of normal; no severe uncontrolled
comorbidity and no other second malignancy. Patients with
central nervous system metastasis were eligible for this study if
they were asymptomatic and had received whole-brain irradiation.
Written informed consent was obtained from all participating
patients before study entry. The pretreatment evaluation included
medical history and physical examination with tumour measure-
ments: chest X-ray, complete blood cell count, serum chemistries,
liver function tests; staging studies to define the extent of
metastatic disease which included abdominal ultrasound, thoracic
and/or abdominal computed tomography (CT), bone scan, as
indicated by clinical or laboratory examination.
Treatment plan
Patients received 10 or 12mgm
 2 mitoxantrone (Novantrone
s)
diluted in 100ml of normal saline over a 30-min intravenous
infusion on day 1. Gemcitabine was administered immediately
after mitoxantrone diluted in 250ml of normal saline in 30min on
days 1 and 8. Using the modified Fibonacci schema (Von Hoff et al,
1984), gemcitabine doses were escalated in subsequent steps, with
a minimum of three patients entered and maintained per dose
level throughout their therapy. The starting dose of 600mgm
 2
gemcitabine was escalated in 200mgm
 2 increments until dose-
limiting toxicity (DLT) developed in three of five patients treated
at a given dose level. After the DLT of gemcitabine was reached, a
mitoxantrone dose level of 12mgm
 2 was tested in combination
with the lowest dosage of gemcitabine in order to obtain a better
balance in dose intensity between the drugs. The chemotherapy
cycle was administered every 3 weeks to a maximum total of eight
cycles for patients with CR, partial response (PR), or stable disease
(SD). With regard to drug supply, mitoxantrone (Novantrone
s)
was currently available in Italy for the treatment of advanced
breast cancer, whereas gemcitabine hydrochloride (Gemzar
s) was
kindly provided by Eli Lilly and Company, Indianapolis, USA.
Toxicity and evaluation of response
Clinical monitoring was performed twice a week with a complete
blood cell count. Toxicity was scored using the World Health
Organization (WHO) criteria (WHO, 1979). At least three patients
were treated at each dose level. To determine the MTD of this
combination, toxicity was assessed if any of these events occurred:
(1) grade 4 thrombocytopenia or grade 4 neutropenia; (2) grade 2
renal or liver dysfunction; (3) any other nonhaematological,
nonhepatic and nonrenal grade 3 toxicity excluding alopecia; and
(4) impossibility of delivering full dose of gemcitabine on day 8
because of grade 2–4 neutropenia or thrombocytopenia. If any of
the side effects reported above was observed in one of three
patients, another patient entered the study at the same dose level.
If DLT was observed in two out of three or four, a fifth patient was
added. If DLT was observed in zero out of three, one out of four or
two out of five patients, respectively, at a single-dose level, we
escalated the dose. If we observed DLT in three out of three, four
or five patients, previous dose level was the MTD recommended
for the phase II trial (best of five schedule). Antitumour activity
was evaluated every two courses (i.e. 6 weeks) on all measurable
lesions. All patients were scheduled for at least two cycles in order
to be eligible for assessment of tumour response. In patients with
tumour responses or SD, the treatment was continued to a
maximum of eight cycles. Tumour response was classified
according to WHO criteria and documented by two investigations
at least 6 weeks apart.
CR was defined as the disappearance of all clinical evidence of
active tumour with complete reossification of bone lesion and the
absence of any disease-related symptoms for a minimum of 4
weeks. PR was defined as a X50% reduction in the sum of the
products of the perpendicular diameters of all measurable lesions,
in absence of any new lesion for at least 4 weeks. In the case of
multiple metastatic sites of disease, the largest masses (up to five)
were considered as the index lesions. Minor response (MR) was
defined as a decrease in tumour size of less than 50% but more
than 25%, for at least 4 weeks. SD was defined as a less than 25%
decrease or a less than 25% increase in tumour size for at least 4
weeks. Progressive disease (PD) was defined as the unequivocal
appearance of any new lesion or an increase of X25% in the sum
of the perpendicular diameters of any measured lesion or in the
estimated size of a not measurable lesion. MR, SD and PD were
considered as treatment failures. The Kaplan–Meier method was
used to analyse the time to progression (TTP) and overall survival
(OS). The confidence intervals (CIs) for the response rates were
calculated using the method described by Simon (1986). The
sequential two steps statistical test of Gehan (1961) was used to
define the number of patients required to detect activity of the
treatment. Cardiotoxicity was carefully monitored. In fact, all
patients before study entry were submitted to physical examina-
tion by a cardiologist, EKG and basal echocardiogram with
measurement of left ventricular ejection fraction (LVEF). Patients
with less than 50% LVEF were excluded from the study.
Echocardiogram was performed every other cycle and patients
were excluded from study continuation if, at any time, their LVEF
decreased by 10% below the initial value, even if they were still
asymptomatic.
RESULTS
From October 1997 to January 2000, 63 women with a median age
of 52 (range 34–69) years, were enrolled into this phase I/II study:
23 patients in the phase I study (three patients at dose levels 1 and
five at dose levels 2, 3, 4 and 5, respectively) and 40 in the
subsequent phase II study. The patient characteristics are shown in
Table 1. It is noteworthy that all patients were previously
submitted to anthracyclines. However, five out of 23 (22%) and
nine out of 40 (22.5%) patients of the phase I and II respectively,
had received anthracyclines in adjuvant setting. Moreover, overall
41 out of 63 (65%) patients had received also taxanes and 34 out of
63 (54%) had received more than one line of chemotherapy
(Table 1).
Dose escalation (phase I)
Twenty-three patients were enrolled into the phase I portion of the
study in five cohorts (Table 2). The dosage of mitoxantrone was
10mgm
 2 in dose levels 1–4 and was escalated to 12mgm
 2 in
the dose level 5. The dosage of gemcitabine was escalated by
200mgm
 2 starting from 600mgm
 2 (dose level 1) to
1200mgm
 2 (dose level 4). Moreover, 600mgm
 2 of gemcitabine
were combined with mitoxantrone 12mgm
 2 in dose level 5. No
DLT was observed in the first three patients treated at dose level 1
(gemcitabine 600mgm
 2). At dose level 2 (gemcitabine
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l800mgm
 2) as well as at dose level 3 (gemcitabine 1000mgm
 2)
two out of five patients had grade 3 neutropenia on day 8 not
allowing drug administration (one patient of the latter group
showed also grade 4 thrombocytopenia). At dose level 3, two of the
five patients treated showed a DLT (one complained neutropenia
and one neutropenia plus thrombocytopenia). Neutropenia, as
DLT, occurred at dose level 4 (gemcitabine 1200mgm
 2). In fact,
at this dose level, three patients had day 8 dose omission because
of grade 3 neutropenia and one of them developed also grade 4
febrile neutropenia (lasting for more than 4 days). Subsequently,
we raised mitoxantrone dose to 12mgm
 2 and combined this drug
with 600mgm
 2 gemcitabine. At these dosages, three out of five
patients had grade 4 neutropenia not allowing further dose
escalation. Thus, the recommended dose level for the phase II
study was gemcitabine 1000mgm
 2 and mitoxantrone 10mgm
 2.
Overall, grades 3 and 4 neutropenia were observed in four out of 23
(17%) and six out of 23 (26%) patients, respectively. Moreover,
neutropenia (febrile in four cases) frequently occurred between
days 11 and 16 of the cycle. The median time to recover from
neutropenia was 9 days (range 3–16). Haematological growth
factors as granulocyte colony stimulating factors (G-CSF) were
given only to patients with febrile neutropenia. Grade 3 or 4
thrombocytopenia were less frequent than neutropenia, occurring
only in two (9%) and one (4%) patients, respectively. A severe
anaemia, requiring red blood cell transfusion, occurred in one
patient affected by liver metastasis and peritoneal carcinosis with
haematic ascites. Nonhaematological toxicity was negligible. One
patient experienced severe vomiting on day 1 of gemcitabine
therapy. Liver transaminase elevation, alopecia, fever and cuta-
neous rash, all of grade 1–2, were observed each in one patient,
respectively. With regard to cardiotoxicity, two patients previously
treated with the maximum dose of anthracyclines showed a
reduction of more than 10% of LVEF as compared to basal value
without any clinical symptom of heart failure.
Of the 23 enrolled patients, three discontinued treatment after
the first or second cycle (one due to early progression, one due to
severe toxicity and one due to refusal to continue), and were
therefore considered treatment failures. Upon disease reevaluation
after the second cycle, there were eight partial responses. At the
fourth cycle evaluation, two out of the eight partial responders
demonstrated CR, while the other six patients remained partial
responders, for an ORR of 35% (95% CI: 21–53%). Responses were
observed at all dose levels. Three (13%) patients had SD and 12
(52%) patients had treatment failure. The five patients who had
prior anthracycline as adjuvant therapy responded. Conversely,
only three (16.5%) out of 18 patients treated with anthracyclines
for advanced disease showed tumour regression when treated with
the combination of gemcitabine plus mitoxantrone.
Phase II
Forty patients were enrolled into this trial and all were assessable
for response and toxicity. Patient characteristics are reported in
Table 1. With regard to the site of disease, of the 40 assessable
women, 14 had liver metastasis and, of these, three had liver
metastasis alone, one liver metastasis plus ascites and 10 liver, lung
and bone metastasis. Moreover, eight patients had bone, five lung
and 13 soft tissues as the only site of disease respectively. All the 40
assessable patients were previously treated with anthracyclines,
and 18 also with taxanes. With regard to previous chemotherapy,
18, nine and 13 patients have been treated, respectively, with one,
two or three chemotherapy regimens before study entry. Nine out
of 18 patients (50%) treated with one chemotherapy regimen only
had received anthracyclines in adjuvant setting. For what concerns
clinical response, no patient showed CR, while PR was observed in
12 patients (30%). Moreover, SD and PD were documented in eight
(20%) and 20 patients (50%), respectively (Table 3). Responses
were observed in six patients with soft-tissue disease, two patients
with liver metastases and four patients with lung, liver and bone
disease. Median time to treatment failure was 22 (range, 2–29)
weeks, median survival was 42 (range, 2–92) weeks and 1-year OS
Table 1 Phases I and II – patient characteristics
Phase I Phase II
No. of patients No. of patients
(N=23) (N=40)
Enrolled 23 40
Median age (years) 52 (range 34–69) 55 (range 37–73)
Performance status (ECOG)
a
0–1 20 40
23
Estrogen receptors
Positive 8 22
Negative 15 7
Unknown 11
Menopausal status
Pre 6 13
Post 17 27
Median disease-free interval (months)
0–12 6 10
12–24 12 21
>24 5 9
Previous anthracyclines 23 40
Adjuvant setting 5 9
Advanced disease setting 18 31
Previous taxanes 16 25
Previous chemotherapy lines
One 11 18
Two 6 9
Three 6 13
Metastatic sites
Viscera 11 19
Bone 6 8
Nodes and soft tissues 6 13
aEastern Cooperative Oncology Group.
Table 2 Number of patients with WHO grade 3 or 4 toxicities and
response by dose level (no. of patients=23)
Dose level
12 3 4 5
Patients treated 3 5 5 5 5
Gemcitabine (mgm
 2) 600 800 1000 1200 600
Mitoxantrone (mgm
 2)1 01 0 1 0 1 01 2
Toxicity
Neutropenia (DLT) F 223 3
Thrombocytopenia FF 1 F 2
Anaemia FF F F 1
Vomiting FF F 1 F
WHO=World Health Organization; DLT=dose-limiting toxicities.
Table 3 Phase II results
Response No. of patients %
Partial response 12 30
Stable disease 8 20
Progression 20 50
Total 40 100
Gemcitabine plus mitoxantrone in metastatic breast cancer
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lwas 22.5%. No statistically significant differences were found in
response rates or in response duration with respect to PS,
menopausal or hormone receptor status, number of metastatic
sites, dominant metastatic site and disease-free survival. The
average dose intensity administered was 78% for gemcitabine and
89% for mitoxantrone. All the 40 assessable patients received at
least one cycle of therapy with a median number of six cycles
(range, 1–10). Of the 187 cycles administered during this trial, 17
(9%) were delayed: 15 because of haematological toxicity and the
remaining two for nonmedical reasons. Moreover, in 15 out of 187
(8%) cycles, doses were reduced as a consequence of haematolo-
gical toxicity and G-CSF was administered in 30 out of 187 cycles
(16%).
Neutropenia resulted in the most common haematological
toxicity observed with a grade 3 and 4 occurring in 13 (32.5%)
and one (2.5%) case, respectively. Grade 3 thrombocytopenia was
observed only in three patients (7.5%), even if no platelet
transfusions were needed. In order to deliver drug at a dose
intensity as close as possible to the planned, G-CSF was
administered in 11 patients with grade 3 and in one patient with
grade 4 neutropenia respectively. Other haematological and
nonhaematological toxicity occurred in few patients. In particular,
grade 3 anaemia and grade 3 mucositis were observed in two cases
(5%), alopecia in one case (2.5%). With regard to cardiac toxicity,
three patients showed a decrease of LVEF of more than 10% below
the initial value and discontinued mitoxantrone after two, four and
five cycles, respectively. These three patients had received a
cumulative dose of epidoxorubicin equal or superior to
450mgm
 2 (Table 4).
DISCUSSION
This study shows that the combination of mitoxantrone
(10mgm
 2 d.1) plus gemcitabine (1000mgm
 2 d.1–8), every 3
weeks, is active and safe in patients affected by advanced breast
cancer previously treated with chemotherapy including anthracy-
clines or taxanes. In fact, these dosages were chosen based on the
phase I study results, although two of the five patients treated at
this dose level showed neutropenia or leuko-thrombocytopenia.
However, in patients subsequently treated in the phase II study,
this dosage resulted very manageable.
Gemcitabine is a novel drug in the treatment of breast cancer.
The first phase II study evaluating this drug in the treatment of
locally advanced or metastatic breast cancer was published by
Carmichael et al (1995). Forty-four patients with one prior
chemotherapy regimen received gemcitabine 800mgm
 2 on days
1, 8, and 15 of a 28-day cycle. Of the 40 evaluable patients, three
(7.5%) achieved CR and seven (17.5%) PR, with an ORR of 25%.
Responses were observed in all measurable metastatic sites (soft
tissue, liver and lung). Median time to response and survival were
1.9 and 11.5 months, respectively. Similar results were reported
with higher doses of gemcitabine in two other phase II studies on
metastatic breast cancer (Blackstein et al, 1997; Spielmann et al,
1997). In particular, Spielmann et al (1997) evaluated 43 women
previously treated with anthracyclines and achieved an ORR of
28% (95% CI 15–44%), with a dose of 1200mgm
 2 given at the
same schedule as above. More recently, with a lower dosage
(1000mgm
 2) and the same schedule, Possinger et al (1999)
reported a 14.3% response, with minimal toxicity, in 42 not
previously treated patients with prevalent visceral disease. How-
ever, despite the modest activity of gemcitabine as single agent in
metastatic breast cancer, its favourable toxicity profile makes it an
ideal candidate for combination chemotherapy. In fact,
Pe ´rez-Manga et al (2000) treated 42 patients with the combination
of gemcitabine and doxorubicin and obtained three complete and
20 partial responses, with an ORR of 55%. Moreover, Mavroudis
et al (1999) with the combination of docetaxel and gemcitabine
plus G-CSF, observed 54% response in anthracycline-pretreated
patients. Nicolaides et al (2000) treated 31 patients, who had
shown progression after a first-line taxanes-based chemotherapy
with the combination of gemcitabine 1000mgm
 2 days 1–8 and
vinorelbine 30mgm
 2 days 1–8. Of 27 evaluable patients, one
(4%) achieved complete remission and five (18%) partial
remission.
Mitoxantrone is an active, well-tolerated drug in the treatment
of advanced breast cancer. A number of studies have demonstrated
that this drug has an activity comparable to anthracyclines, but it
is much less toxic (Bennett et al, 1988; Henderson et al, 1989).
Given as a single agent, mitoxantrone is able to achieve up to 27%
response in patients previously treated with chemotherapy
(Brufman et al, 1993). Moreover, an incomplete cross resistance
with doxorubicin has been suggested. In fact, Smith et al (1983),
with mitoxantrone as single agent, reported three out of nine
responses in patients refractory to doxorubicin. Furthermore, the
rationale for the use of a mitoxantrone combination after
anthracyclines is given by the results reported by Panagos et al
(Panagos, 1997) and Susnjar et al (1999). In fact, the former, using
a combination of mitoxantrone and paclitaxel, observed seven
partial remissions plus six minor responses or disease stabilisation
out of 14 anthracycline pretreated patients, and the latter, using a
combination of mitoxantrone plus folinic acid and fluorouracil,
reported a high percentage of response in doxorubicin-resistant
breast cancer.
It is noteworthy that, although the potential high risk of cardiac
toxicity from mitoxantrone, in patients previously treated with
anthracyclines, cardiac dysfunction was only seldom reported in
the above mentioned studies. Also in the present study, five out of
63 patients (8%) showed a drop of more than 10% of LVEF as
compared to basal value, without any sign or symptom of cardiac
toxicity. It is likely that the reason for the low incidence of clinical
cardiotoxicity in our study is because cardiac function was closely
monitored, thus allowing patients to discontinue treatment prior
to clinical evidence of cardiac toxicity.
In conclusion, the high activity of mitoxantrone in breast cancer
and the suggested activity with low toxicity profile for gemcitabine
Table 4 Cardiac toxicities in patients who received mitoxantrone
Cumulative LVEF %
Patients no. 5
dose
(mgm
 2) Before After
Prior anthracyclines
(mgm
 2)
Symptom
and sign
(1) Phase I 45 55 40 Doxo 300 Asymptomatic
(2) Phase I 65 55 45 Doxo 280 Asymptomatic
(3) Phase II 20 55 43 Epi 480 Asymptomatic
(4) Phase II 40 50 37 Epi 480 Tachycardia
(5) Phase II 50 60 45 Epi 450 Asymptomatic
Epi=epidoxorubicin, Doxo=doxorubicin.
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definition of the MTD and the assessment of efficacy of this
combination. The dose of gemcitabine of 1000mgm
 2 on days 1
and 8 plus mitoxantrone 10mgm
 2 on day 1 of a 3-week schedule,
obtained 30% partial response in 40 patients. Our data show that
the administration of these two drugs was associated with a
manageable haematological toxicity and negligible nonhaematolo-
gical side effects. Also the fearful cardiac dysfunction that might be
expected in high percentage in these patients, because of their
prior anthracycline treatment, was a minor problem. Further
studies in less heavily pretreated patients are warranted with this
combination.
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